Trial
NCT01509053
Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborators
—
Condition
Schizophrenia
Intervention
Aripiprazole (Abilify®) IM Depot Injection
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-03-04